ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programs and its suite of product development and GMP cell processing services.

佛罗里达州奥蒙德海滩（OrmondBeach）和马里兰州日耳曼敦（GERMANTOWN），2024年4月10日（global NEWSWIRE）--模块化洁净室基础设施和服务的领先创新者Germfree，以及分散细胞和基因治疗（CGTs）的全球领军者Orgenesis Inc.（纳斯达克：ORGS），今天宣布了一项资产购买和战略合作伙伴关系，旨在推进Orgenesis的治疗计划及其产品开发和GMP细胞处理服务套件。

The collaboration’s goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide. By combining Germfree’s expertise in designing, manufacturing, and maintaining advanced manufacturing facility environments with Orgenesis’ cutting-edge processes and analytical development capabilities, the partnership seeks to significantly reduce the production costs of cell and gene therapy products.

该合作的目标是改变细胞和基因疗法的生产，使这些重要的疗法更经济实惠，并为全世界的患者所接受。通过将Germfree在设计、制造和维护先进制造设施环境方面的专业知识与Orgenesis的尖端工艺和分析开发能力相结合，该合作伙伴关系旨在显着降低细胞和基因治疗产品的生产成本。

The ultimate goal is to enable broader adoption of life-saving treatments. Vered Caplan, CEO of Orgenesis, stated, “Under the agreement, Orgenesis and Germfree will join forces to co-market Orgenesis’ decentralized Octomera service platform, and its Octomera Mobile Processing Units and Labs (OMPULs™) globally.

最终目标是更广泛地采用挽救生命的治疗方法。Orgenesis首席执行官Vered Caplan表示，“根据协议，Orgenesis和Germfree将联手在全球共同销售Orgenesis分散的Octomera服务平台及其Octomera移动处理单元和实验室（OMPULs™）。

The partnership marks a significant milestone in the bio-manufacturing industry, as the industry begins to pivot to the paradigm-shifting distributed processing of cell and gene therapies (CGTs). Germfree will be marketing, manufacturing, and servicing OMPULs as part of its modular cleanroom fleet, enabling Orgenesis to focus on its therapeutic pipeline with an emphasis on immuno-oncology.

该伙伴关系标志着生物制造业的一个重要里程碑，因为该行业开始转向细胞和基因疗法（CGT）的范式转变分布式处理。Germfree将作为其模块化洁净室团队的一部分，对OMPULs进行营销、制造和服务，使Orgenesis能够专注于其治疗管道，重点是免疫肿瘤学。

We are delighted to work with Germfree to meet the growing demand for our platform.” Victor Miller, CFO of Orgenesis, remarked on the financial and strategic significance of the par.

我们很高兴与Germfree合作，以满足对我们平台不断增长的需求。”Orgenesis首席财务官维克多·米勒（VictorMiller）评论了par的财务和战略意义。